← ANALYST RATINGS · TIPRANKS
SpyGlass Pharma (SGP): analyst forecast and price target
Analyst consensus
Strong Buy3 Buy0 Hold0 Sell
Ratings of 3 analysts in the last 3 months12-month forecast
Based on 3 price targets given in the last 3 months, the average target is $39.33, the highest $42.00, the lowest $37.00. The average is +63.9% from the last price of $24.00.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Yi Chen★★★★★★★★★★#10518 · hits 41% · avg −1.0% | H.C. Wainwright | $37.00 | Buy | +54.2% | Reiterated | 05.10.26on TipRanks 06:55 | +2.0%next day −3.7% · 5 days −3.3% | ↗ |
| Thomas Stephan★★★★★★★★★★#3049 · hits 47% · avg +8.4% | Stifel Nicolaus | $42.00 | Buy | +75.0% | Reiterated | 02.10.26on TipRanks 09:15 | −6.7%next day +2.0% · 5 days −1.2% | ↗ |
| Christopher Raymond★★★★★★★★★★#4074 · hits 45% · avg +2.6% | Raymond James | $39.00 | Buy | +62.5% | Initiated | 14.08.26on TipRanks 06:50 | +4.3%next day −1.1% · 5 days +2.6% | ↗ |
| Yi Chen★★★★★★★★★★#10518 · hits 41% · avg −1.0% | H.C. Wainwright | $37.00 | Buy | +54.2% | Reiterated | 10.08.26on TipRanks Aug 7 16:45 | −0.6%next day −0.9% · 5 days +2.5% | ↗ |
| Dennis Ding★★★★★★★★★★#2230 · hits 58% · avg +12.3% | Jefferies | $62.00 | Buy | +158.3% | Reiterated | 19.05.26on TipRanks 09:35 | −4.0%next day +2.2% · 5 days −7.1% | ↗ |
| Thomas Stephan★★★★★★★★★★#3049 · hits 47% · avg +8.4% | Stifel Nicolaus | $42.00 | Buy | +75.0% | Reiterated | 15.05.26on TipRanks 11:07 | −3.2%next day −4.1% · 5 days −11.1% | ↗ |
| Yigal Nochomovitz★★★★★★★★★★#616 · hits 51% · avg +15.1% | Citi | $42.00 | Buy | +75.0% | Reiterated | 09.03.26on TipRanks Mar 10 06:55 | +0.8%next day −0.9% · 5 days +1.3% | ↗ |
| Marc Goodman★★★★★★★★★★#365 · hits 56% · avg +19.2% | Leerink Partners | $42.00 | Buy | +75.0% | Initiated | 03.03.26on TipRanks 06:45 | +1.0%next day −1.0% · 5 days +0.7% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering SpyGlass Pharma
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $38.00 at a price of $26.00 (+46.2%); now: $39.33 at $24.00 (+63.9%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 11 | 3 | 3 | 0 | 0 | 1 |
| Buy | 1 | 0 | 0 | 2 | 2 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Best top-analyst consensus in the sector · General
About SpyGlass Pharma
- CEO: Patrick H. Mooney
- Employees: 76
- 15326 Alton Parkway, Irvine, CA, 92618, US
- www.spyglasspharma.com
SpyGlass Pharma, Inc. is an advanced biopharmaceutical company dedicated to developing innovative therapeutic approaches for individuals suffering from chronic eye conditions. Its flagship investigational product, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), is engineered for implantation during standard cataract removal procedures with the aim of reducing elevated intraocular pressure (IOP) in patients afflicted with either open-angle glaucoma (OAG) or ocular hypertension (OHT). Co-founded in January 2019 by Malik Y. Kahook and Glenn Sussman, the company maintains its headquarters in Aliso Viejo, CA.
Data from the stock’s TipRanks forecast page, read 176 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗